A phase IV, multicenter single-arm, open-label study to assess the efficecy and safety of Tocilizumab in Chinese patients with systemic juvenile idiopathic arthritis

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPB-17013704

Enrollment

Unknown

Registered

2017-12-05

Start date

2017-12-20

Completion date

Unknown

Last updated

2017-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

systemic juvenile idiopathic arthritis

Interventions

Case series:Tocilizumab

Eligibility

Sex/Gender

All

Age

2 Years to 17 Years

Inclusion criteria

Inclusion criteria: 1. Patient of systemic juvenile idiopathic arthritis from 2 to 17; 2. Persistent illness activity >=6 months 3. Untreated by biologics before our research; 4. No oral Glucocorticoid or NSAISs.

Exclusion criteria

Exclusion criteria: 1. The general standard (4); 2. The general safety standard (16).

Design outcomes

Primary

Measure	Time frame
ACR30;	—

Countries

China

Contacts

Public ContactXUEMEI TANG

Children's Hospital of Chongqing Medical University

tangxuemei2008@163.com+86 13012352441

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026